Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019409 | 0.87 | MAPK14 (0.38) | MAPK14ALDH1A1KDM4ENPSR1BRD4 | |
| SCHEMBL4832587 | 0.86 | CYP1A2 (0.44) | MAPK14ALDH1A1KDM4EMAPTMAPK1 | |
| SCHEMBL4844936 | 0.86 | MAPK14 (0.41) | MAPK14ALDH1A1KDM4EBRD4 | |
| SCHEMBL4837598 | 0.86 | ALDH1A1 (0.42) | MAPK14ALDH1A1KDM4ENPSR1 | |
| SCHEMBL4837424 | 0.85 | EGFR (0.41) | MAPK14KDM4EBRD4 | |
| SCHEMBL4841046 | 0.84 | SMN1; SMN2 (0.42) | MAPK14ALDH1A1NPSR1MAPTMAPK1 | |
| SCHEMBL4841631 | 0.83 | MAPK14 (0.39) | MAPK14 | |
| SCHEMBL4842380 | 0.81 | MAPK14 (0.39) | MAPK14ALDH1A1KDM4EBRD4 | |
| SCHEMBL4021743 | 0.80 | BRD4 (0.40) | MAPK14ALDH1A1KDM4ENPSR1SLC2A1 | |
| SCHEMBL4840538 | 0.80 | KMT2A (0.38) | MAPK14KDM4EBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | MAPK14 33/4885ALDH1A1 3313/4885KDM4E 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.